STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3

被引:5
|
作者
Seki, Y
Suzuki, N
Imaizumi, M
Iwamoto, T
Usami, N
Ueda, Y
Hamaguchi, M
机构
[1] Nagoya Univ, Grad Sch Med, Div Canc Biol, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Thorac Surg, Showa Ku, Nagoya, Aichi 4668550, Japan
关键词
signal transduction; MAPK; STAT3; JAB; human lung cancer; carcinogenesis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To search for the signaling events in lung carcinoma relevant to its tumorigenesis, we investigated the phosphorylation of MAPK and STAT3 in human lung carcinoma tissues and their paired normal tissues. Although relative amounts of MAPK levels differed among the cases examined, no clear difference in MAPK levels was observed between tumor tissues and their paired normal tissues. Of 79 cases examined, only 7 cases (8.9%) showed tumor-specific phosphorylation of MAPK, whereas 41 cases (52%) showed more than 2-fold lower levels of MAPK phosphorylation in tumor tissues. In contrast to MAPK, 42 cases (53%) showed tumor-specific increase in STAT3 expression. In addition, 15 cases (19%) showed tumor-specific increase of STAT3 phosphorylation and 51 cases (65%) had STAT3 phosphorylation proportional to its expression. Moreover, exogenous expression of either JAB or dominant negative STAT3 in lung carcinoma cell lines led to the suppression of STAT3 phosphorylation and the drastic reduction of anchorage-independent growth of the cells. Taken together, our results suggest that JAK-STAT3 signaling has a pivotal role for oncogenic growth of lung carcinoma cells.
引用
收藏
页码:931 / 934
页数:4
相关论文
共 50 条
  • [31] Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain
    Hua, Yaping
    Yuan, Xing
    Shen, Yun-heng
    Wang, Jinxin
    Azeem, Waqas
    Yang, Shuo
    Gade, Alexandra
    Lellahi, Seyed Mohammad
    oyan, Anne Margrete
    Ke, Xisong
    Zhang, Wei-dong
    Kalland, Karl-Henning
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] Targeting STAT3 and STAT5 in Cancer
    de Araujo, Elvin D.
    Keseru, Gyorgy M.
    Gunning, Patrick T.
    Moriggl, Richard
    CANCERS, 2020, 12 (08)
  • [33] Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2
    Richard A Steinman
    Abbey Wentzel
    Yalin Lu
    Christine Stehle
    Jennifer Rubin Grandis
    Oncogene, 2003, 22 : 3608 - 3615
  • [34] Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2
    Steinman, RA
    Wentzel, A
    Lu, YL
    Stehle, C
    Grandis, JR
    ONCOGENE, 2003, 22 (23) : 3608 - 3615
  • [35] STAT3α Is Oncogenic for Endometrial Carcinoma Cells and Mediates the Oncogenic Effects of Autocrine Human Growth Hormone
    Tang, Jian-Zhong
    Kong, Xiang-Jun
    Banerjee, Arindam
    Muniraj, Nethaji
    Pandey, Vijay
    Steiner, Michael
    Perry, Jo K.
    Zhu, Tao
    Liu, Dong-Xu
    Lobie, Peter E.
    ENDOCRINOLOGY, 2010, 151 (09) : 4133 - 4145
  • [36] Activating mutations of STAT3: Impact on human growth
    Gutierrez, Mariana
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2020, 518
  • [37] Identification and characterization of cis elements in the STAT3 gene regulating STAT3α and STAT3β messenger RNA splicing
    Shao, H
    Quintero, AJ
    Tweardy, DJ
    BLOOD, 2001, 98 (13) : 3853 - 3856
  • [38] Functional differences between Stat3 alpha and Stat3 beta
    Schaefer, TS
    Sanders, LK
    Park, OK
    Nathans, D
    MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (09) : 5307 - 5316
  • [39] Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing
    Dong, Yushan
    Chen, Jingyu
    Chen, Yuhan
    Liu, Songjiang
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 167
  • [40] Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells
    W Okamoto
    I Okamoto
    T Arao
    K Yanagihara
    K Nishio
    K Nakagawa
    British Journal of Cancer, 2011, 105 : 407 - 412